

**Supplemental File 1. Table S1.** Frequency and prognosis value of cytogenetic and molecular genetic abnormalities identified in ALL.

Genetic abnormalities [1–8]	Whole cohort [1,9,10]	Pediatric	Adult	Prognosis [3,11–15]
<b>B-ALL</b>				
Hyperdiploidy (>50 and <60 chromosomes)	20%–30%	25%	5–10%	Favorable
Near-haploid 24–31 chromosomes	1–3%			Adverse
Low hypodiploid 32–39 chromosomes	1–3%			Adverse
High hypodiploid 40–43 chromosomes	1–3%			Adverse
Near-diploid 44–45 chromosomes				Favorable
<i>TEL-AML1 (ETV6-RUNX1) t(12;21)</i>	15–25%	20–30%	2%	Favorable
<i>KMT2A (MLL) rearranged t(v;11q23)</i>	5–6%	8%	10%	Adverse
<i>E2A-PBX1(TCF3-PBX1) t(1;19)</i>	2–6%	5%	3%	Favorable
<i>BCR-ABL t(9;22)</i>	2–5%	2–4%	25%	Improved *
<i>IL3-IGH@ t(5;14)(q31;q32)</i>	rare	<1%	<1%	Intermediate
<i>CRLF2 rearrangement (IGH-CRLF2; P2RY8-CRLF2)</i>	5–7%			Adverse **
<i>BCR-ABL1-like' or Ph-like</i>	10–15%	10%	20%	Adverse
iAMP21	2%			Adverse
<i>TCF3-HLF t(17;19)</i>	<0.5%			Adverse
<i>DUX4- and ERG-deregulated</i>				Favorable
<i>MEF2D-rearranged</i>		3% to 4%	6%	Unknown
<i>ZNF384-rearranged</i>		3%	7%	Unknown
<i>PAX5 rearrangement</i>	2%			Unknown
<b>T-ALL</b>				
<b>TCR rearrangements</b>				
<i>TLX1 (HOX11) (10q24)</i>	5–10%	7%	30%	Favorable
<i>TLX3 (HOX11L2) (5q35)</i>	20–25%	20%	10–15%	Adverse ***
<i>TAL1(SCL) (1p32)</i>	15–18%	7%	12%	Favorable
<i>TAL2 (9q34)</i>	<1%			Unknown
<i>LMO1/ RBTN1 (11p15)</i>	10%			Favorable
<i>LMO2/RBTN2 (11p13)</i>	10%			Favorable
<i>LYL1 (19p13)</i>	<1%	1.5%	3%	Adverse
<i>BHLHB1 (21q22)</i>	<1%			Unknown
<i>LCK (1p34)</i>	<1%			Unknown
<i>NOTCH1/TAN1 (9q34)</i>	<1%			Unknown
<i>MYC (8q24)</i>				Unknown
<i>TCL1(14q32)</i>				Unknown
<i>CCND2 (12p13.32)</i>	<1%			Unknown
<i>MTCP1 (Xq28)</i>				Unknown
<b>Non-TCR rearrangements</b>				
<i>SIL-TAL1(SCL)</i>	9–30%			Unknown
<i>PICALM(CALM)-MLLT10(AF10)</i>	5–10%			Unknown
<i>E2A/PBX1</i>				Unknown
<i>NOTCH1(TAN1)-fusions</i>				Unknown
<i>KMT2A (MLL)-MLLT1(ENL)</i>	2–5%	0.2%	0.5%	Favorable
<i>KMT2A (MLL) rearrangements</i>	5%			Adverse
<i>NUP98-SETBP1</i>				Unknown
<i>NUP98-RAP1GDS1</i>				Unknown
<i>NUP98-ADD3</i>				Unknown
<i>BCR-ABL1(Ph+)</i>	<1%			Adverse
<i>EML1-ABL1</i>	<1%			Unknown

<i>NUP214(CAN)-ABL1(ABL)</i>	5–15%			Adverse (some studies), intermediate (other studies)
<i>SET/NUP214</i>				Unknown
<i>ETV6(TEL)-JAK2</i>	<1%			Unknown
Early T-cell precursor				Adverse

**Abbreviations:** ALL= acute lymphoblastic leukemia. \* With TKI therapy. \*\* In non-Down syndrome-associated ALL. \*\*\* In some studies.

## References

- Iacobucci, I.; Mullighan, C.G. Genetic basis of acute lymphoblastic leukemia. *J. Clin. Oncol.* **2017**, *35*, 975–983.
- Chiaretti, S.; Foa, R. T-cell acute lymphoblastic leukemia. *Haematologica* **2009**, *94*, 160–162.
- Woo, J.S.; Alberti, M.O.; Tirado, C.A. Childhood b-acute lymphoblastic leukemia: A genetic update. *Exp. Hematol. Oncol.* **2014**, *3*, 16.
- Zhang, L.; Rossi, M.R.; Fisher, K.E. Section ii: Hematolymphoid malignancies. *Curr. Probl. Cancer* **2014**, *38*, 159–174.
- Hunger, S.P.; Mullighan, C.G. Redefining all classification: Toward detecting high-risk all and implementing precision medicine. *Blood* **2015**, *125*, 3977–3987.
- Chen, B.; Jiang, L.; Zhong, M.L.; Li, J.F.; Li, B.S.; Peng, L.J.; Dai, Y.T.; Cui, B.W.; Yan, T.Q.; Zhang, W.N.; et al. Identification of fusion genes and characterization of transcriptome features in t-cell acute lymphoblastic leukemia. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 373–378.
- Atak, Z.K.; Gianfelici, V.; Hulselmans, G.; De Keersmaecker, K.; Devasia, A.G.; Geerdens, E.; Mentens, N.; Chiaretti, S.; Durinck, K.; Uyttebroeck, A.; et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in t-cell acute lymphoblastic leukemia. *PLoS Genet.* **2013**, *9*, e1003997.
- Neumann, M.; Vosberg, S.; Schlee, C.; Heesch, S.; Schwartz, S.; Gokbuget, N.; Hoelzer, D.; Graf, A.; Krebs, S.; Bartram, I.; et al. Mutational spectrum of adult t-all. *Oncotarget* **2015**, *6*, 2754–2766.
- Tasian, S.K.; Loh, M.L.; Hunger, S.P. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. *Cancer* **2015**, *121*, 3577–3590.
- Taylor, J.; Xiao, W.; Abdel-Wahab, O. Diagnosis and classification of hematologic malignancies on the basis of genetics. *Blood* **2017**, *130*, 410–423.
- Pui, C.H.; Jeha, S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. *Nat. Rev. Drug Discov.* **2007**, *6*, 149–165.
- Inaba, H.; Greaves, M.; Mullighan, C.G. Acute lymphoblastic leukaemia. *Lancet* **2013**, *381*, 1943–1955.
- Gowda, C.; Dovat, S. Genetic targets in pediatric acute lymphoblastic leukemia. *Adv. Exp. Med. Biol.* **2013**, *779*, 327–340.
- Zuckerman, T.; Rowe, J.M. Pathogenesis and prognostication in acute lymphoblastic leukemia. *F1000prime Rep.* **2014**, *6*, 59.
- Moorman, A.V. New and emerging prognostic and predictive genetic biomarkers in b-cell precursor acute lymphoblastic leukemia. *Haematologica* **2016**, *101*, 407–416.